Company Description
Q Biomed (OTC Link: QBIO) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $14.5K.
QBIO stock has declined 100.0% over the past year. Shares last traded at $0.0000.
On a trailing twelve-month basis, Q Biomed reported revenue of $284K with net income of -$2.1M and diluted earnings per share of $-0.08. The company operates at a net profit margin of -721.7%.
This page provides a comprehensive overview of QBIO stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Q Biomed (QBIO) stock last traded at $0.0000. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $14.5K, QBIO is classified as a micro-cap stock with approximately 145.1M shares outstanding.
Latest News
Q Biomed has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial. View all QBIO news →
SEC Filings
Financial Highlights
Q Biomed generated $284K in revenue over the trailing twelve months, retaining a -3.2% gross margin, operating income reached -$3.4M (-1211.7% operating margin), and net income was -$2.1M, reflecting a -721.7% net profit margin. Diluted earnings per share stood at $-0.08. The company generated $1.9M in operating cash flow. With a current ratio of 0.01, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
QBIO Company Profile & Sector Positioning
Q Biomed (QBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing QBIO often look at related companies in the same sector, including Biostax Corp (BTAX), Scopus Biopharma Inc. (SCPS), Virpax Pharmaceuticals Inc (VRPX), Evelo Biosciences (EVLO), and PaxMedica, Inc. (PXMD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate QBIO's relative position within its industry.